Cic-Mutation As A Potential Molecular Mechanism Of Acquired Resistance To Combined Braf/Mek Inhibition In Cns Multiple Myeloma

Matteo Claudio Da Via,Antonio Giovanni Solimando,Andoni Garitano-Trojaola,Santiago Barrio,Nadine Rodhes,Susanne Strifler,Eva Teufel,Constantin Lapa, Hermann Einsele,Andreas Beilhack,K. Martin Kortüm

BLOOD（2018）

引用 3|浏览10

暂无评分

摘要

Central nervous system (CNS) involvement is an extremely rare extramedullary multiple myeloma (MM) manifestation, diagnosed in less than 1% of patients. It is considered an ultimate high-risk feature, associated with unfavorable cytogenetics, and, even with intense treatment applied, survival is short, reaching less than 12 months in most cases.

查看译文

关键词

multiple myeloma,braf/mek inhibition,cic-mutation

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要